Fiera Capital Corp Purchases 40,740 Shares of Eli Lilly and Company $LLY

Fiera Capital Corp boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 7,327.3% in the fourth quarter, Holdings Channel reports. The firm owned 41,296 shares of the company’s stock after purchasing an additional 40,740 shares during the period. Fiera Capital Corp’s holdings in Eli Lilly and Company were worth $44,380,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the period. 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares in the last quarter. Finally, Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $33,000. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage data for retatrutide showed strong weight-loss results and benefits for obesity-linked conditions, helping convince investors that Lilly can extend its lead in the fast-growing GLP-1 market. Reuters: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: Lilly also reported encouraging Phase 3 results for Foundayo (orforglipron), its oral GLP-1 drug, including better A1C control and weight loss than oral semaglutide in a head-to-head study, with FDA submission planned by the end of the second quarter. PR Newswire: Lilly’s oral GLP-1 Foundayo delivered superior A1C control and weight loss
• Positive Sentiment: Additional ADA conference updates showed Foundayo produced meaningful weight loss in women across menopause stages, broadening the potential patient population and supporting the drug’s commercial opportunity. PR Newswire: Foundayo associated with significant weight loss in women at every stage of menopause
• Positive Sentiment: Peer weakness also appears to be helping Lilly: Zealand Pharma’s disappointing GLP-1 data and a selloff in competing obesity names highlighted Lilly’s relative advantage in the weight-loss race. The Motley Fool: A Weight-Loss Rival Just Crashed 23%
• Neutral Sentiment: Lilly’s 340B deadline passed and hospitals are now evaluating the implications; this looks more like a policy/pricing issue than an immediate earnings catalyst. Becker’s Hospital Review: Eli Lilly’s 340B deadline passes
• Neutral Sentiment: Reports that Medicare’s GLP-1 bridge program may test Lilly’s obesity strategy add some uncertainty, but the impact is still unclear. MSN: Eli Lilly faces new test with Medicare GLP-1 Bridge program
• Neutral Sentiment: Lilly also completed a bioavailability study for early-stage asset LY4064809, which is a pipeline update but not likely a near-term stock driver. TipRanks: Lilly advances early-stage asset with completion of LY4064809 bioavailability study

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,149.38 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.83, a price-to-earnings-growth ratio of 1.24 and a beta of 0.53. The stock’s 50-day moving average is $979.60 and its 200-day moving average is $1,013.80. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the company earned $3.34 earnings per share. Eli Lilly and Company’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Guggenheim restated a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Rothschild & Co Redburn boosted their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.